

<b>Outcome</b>	<b>HT</b>	<b>T-DM1</b>	<b>T-DM1 + P</b>
<b>Follow-up mediano (mesi)</b>	34.8	34.9	34.7
<b>PFS mediana (mesi)</b>	13.7	14.1	15.2
<b>Hazard ratio [97.5% CI]</b>	-	0.91 [0.73–1.13], p = 0.31 vs HT	0.87 [0.69–1.08], p = 0.14 vs HT 0.91 [0.73–1.13], p = 0.31 vs T-DM1
<b>ORR, %</b>	67.9	59.7	64.2
<b>Durata mediana della risposta (mesi)</b>	12.5	20.7	21.2
<b>Effetti collaterali di grado <math>\geq 3</math> %</b>	54.1	45.4	46.2
<b>Neutropenia</b>	19.8	4.4	2.7
<b>Neutropenia febbrile</b>	6.5	0	0
<b>Anemia</b>	2.8	4.7	6.0
<b>Incremento di AST</b>	0.3	6.6	3.0
<b>Trombocitopenia</b>	0	6.4	7.9